Selective AXL inhibitors
Oral presentation at SITC during High Impact Clinical Trials session:
Friday, 8th November 2019: 5:10 pm – 5:25 pm
A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis.
For more information, please contact: post@bergenbio.com.
Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.
